Retatrutide

Retatrutide is a synthetic peptide in the class of multi-receptor incretin agonists, engineered to engage three related receptors: GLP-1R, GIPR and GCGR. These are class B G protein-coupled receptors within the incretin signalling system, a hormone network coordinating metabolic communication between the pancreas, gastrointestinal tract, liver and brain.

Researchers globally can buy retatrutide 10 mg from Zypep Peptides Co., Limited (zypep.com). This is a high-purity research peptide independently tested by accredited laboratories for peptide identity, purity, and analytical consistency. Certificates of Analysis are available for every product batch to give researchers full transparency, traceability, and quality documentation as expected for advanced incretin and metabolic research compounds.

Retatrutide Structure and Design

Structurally, retatrutide is built on a GIP peptide backbone with targeted substitutions that introduce cross-reactivity at the GLP-1 and glucagon receptors. Several key modifications contribute to its receptor activity and pharmacokinetic profile:

Aib² (2-aminoisobutyric acid) at position 2 increases resistance to degradation by dipeptidyl peptidase-4 (DPP-4), contributing to the peptide’s prolonged biological activity.

αMeLeu¹³ (α-methylleucine) at position 13 enhances activity at both the GIP and glucagon receptors while helping maintain balanced multi-receptor agonism.

Aib²⁰ (2-aminoisobutyric acid) at position 20 contributes to the peptide’s pharmacokinetic properties and supports its GIP receptor activity.

C-terminal amidation reduces susceptibility to degradation by carboxypeptidases, improving overall peptide stability.

The molecule carries a C20 fatty diacid conjugated through a gamma-glutamate and AEEA linker at a lysine side chain. This enables reversible albumin binding, which drives the long circulating half-life of roughly six days and underpins the once-weekly schedule used across its clinical programme.

The third receptor is what separates retatrutide from dual GLP-1/GIP agonists like Tirzepatide. Dual agonists engage GIP and GLP-1. Adding glucagon receptor activity brings in a pathway associated with energy expenditure and hepatic fat oxidation, giving researchers a tool for studying multi-pathway metabolic regulation rather than appetite and glycaemic signalling alone.

Chemical properties and registry information

Clinical data and research background

Retatrutide is one of the newest investigational peptides in the incretin field and has attracted considerable scientific interest owing to its unique triple-receptor mechanism of action. Since its development, published preclinical and clinical studies have investigated its pharmacology, receptor biology, pharmacokinetics, and physiological effects, making retatrutide an increasingly important research tool for the study of metabolic and endocrine signalling.

Researchers looking to buy retatrutide should note that the studies summarised below are presented solely to describe the current scientific literature and should not be interpreted as evidence of clinical efficacy or authorised therapeutic use of the research material supplied by Zypep Peptides.

Phase 2 proof-of-concept study (Jastreboff et al., 2023)

One of the landmark publications in retatrutide research was the Phase 2 randomised, double-blind, placebo-controlled study published in the New England Journal of Medicine in 2023. The trial established the first comprehensive clinical characterisation of retatrutide across multiple dose levels over a 48-week treatment period, providing valuable information regarding its pharmacokinetics, safety profile, and biological activity. At the highest dose evaluated, investigators reported a mean body-weight reduction of 24.2%, supporting continued investigation of triple-receptor agonism in larger clinical programmes.

The Phase 3 TRIUMPH programme

Building on these findings, retatrutide progressed into the international TRIUMPH Phase 3 programme. Among the first studies to report results was TRIUMPH-4, a 68-week randomised, double-blind, placebo-controlled trial assessing long-term weight management and cardiometabolic biomarkers in adult obese cohorts. These published datasets serve as primary reference material for comparative triple-incretin laboratory research.

Global wholesale research supply

Zypep Peptides provides factory-direct bulk retatrutide lyophilized powder for academic labs, preclinical CROs and peptide research distributors. Submit your inquiry via the website floating chat dialog on zypep.com to receive custom bulk pricing, full batch COA and international shipping details. All products sold exclusively for laboratory research use, not for human consumption.